Get informed when a big investor buys or sells
+ FollowNovember 11, 2026 - AI Summary
Undervalued by 203.7% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $8.68 Billion |
|---|---|
| Enterprise Value | $13.67 Billion |
| Annual dividend | $0.18 |
| Dividend yield | 1.94% |
| Earnings per Share | $3.21 |
| Beta | 0.26 |
| Outstanding Shares | 992,149,181 |
| P/E Ratio | 14.54 |
|---|---|
| PEG | 96.41 |
| Price to Sales | 0.34 |
| Price to Book Ratio | 0.31 |
| Enterprise Value to Revenue | 0.52 |
| Enterprise Value to EBIT | 2.05 |
| Enterprise Value to Net Income | 3 |
| Total Debt to Enterprise | 0.63 |
| Debt to Equity | 0.31 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
H. Lundbeck A/S operates as an international biopharmaceutical entity, focusing its efforts on the entire lifecycle of pharmaceutical products—from initial research and development to manufacturing and global sales. The firm primarily sp...